PE20130326A1 - GLUCAGON ANALOGS - Google Patents
GLUCAGON ANALOGSInfo
- Publication number
- PE20130326A1 PE20130326A1 PE2012002434A PE2012002434A PE20130326A1 PE 20130326 A1 PE20130326 A1 PE 20130326A1 PE 2012002434 A PE2012002434 A PE 2012002434A PE 2012002434 A PE2012002434 A PE 2012002434A PE 20130326 A1 PE20130326 A1 PE 20130326A1
- Authority
- PE
- Peru
- Prior art keywords
- ser
- leu
- lys
- tyr
- glu
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- -1 Ala Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A ANALOGOS DE GLUCAGON DE FORMULA R1-X-Z-R2 DONDE R1 ES H, ALQUILO(C1-C4), ACETILO, FORMILO, ENTRE OTROS; R2 ES OH O NH2; X ES UN PEPTIDO DE FORMULA His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-X16-X17-Arg-Ala-X20-Asp-Phe-Ile-Glu-Trp-Leu-X27-X28-X29 EN DONDE X2 ES Ser Y Aib; X16 ES Glu E Y; X17 ES Arg E Y; X20 ES Lys E Y; X27 ES Leu E Y; X28 ESTA AUSENTE O ES Ser E Y; X29 ESTA AUSENTE O ES Ala; Y ES Lys, Cys O Orn; Z ESTA AUSENTE O ES UNA SECUENCIA DE 1 A 20 UNIDADES DE AMINOACIDOS TALES COMO Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr Y Orn; EN DONDE LA CADENA LATERAL DE UN RESIDUO AMINOACIDICO Y DE X ESTA CONJUGADA CON UN SUSTITUYENTE LIPOFILO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE OBESIDAD, HIPERTENSION, ATEROESCLEROSIS, CARDIOPATIA CORONARIAREFERS TO GLUCAGON ANALOGS OF FORMULA R1-X-Z-R2 WHERE R1 IS H, ALKYL (C1-C4), ACETYL, FORMYL, AMONG OTHERS; R2 IS OH OR NH2; X IS A PEPTIDE OF FORMULA His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-X16-X17-Arg-Ala-X20-Asp-Phe- Ile-Glu-Trp-Leu-X27-X28-X29 WHERE X2 IS Ser Y Aib; X16 IS Glu E Y; X17 IS Arg E Y; X20 IS Lys E Y; X27 IS Leu E Y; X28 IS ABSENT OR IS Ser E Y; X29 IS ABSENT OR IS Ala; AND IS Lys, Cys O Orn; Z IS ABSENT OR IS A SEQUENCE OF 1 TO 20 UNITS OF AMINO ACIDS SUCH AS Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr AND Orn; WHERE THE LATERAL CHAIN OF AN AMINO ACID AND X RESIDUE IS CONJUGATED WITH A LIPOFIL SUBSTITUTE. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT IS USEFUL IN THE TREATMENT OF OBESITY, HYPERTENSION, ATHEROSCLEROSIS, CORONARY CARDIOPATHY
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201000550 | 2010-06-23 | ||
| US35862310P | 2010-06-25 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130326A1 true PE20130326A1 (en) | 2013-03-17 |
Family
ID=44630045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002434A PE20130326A1 (en) | 2010-06-23 | 2011-06-23 | GLUCAGON ANALOGS |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9403894B2 (en) |
| EP (1) | EP2585481B1 (en) |
| JP (1) | JP5937582B2 (en) |
| KR (1) | KR20130086339A (en) |
| CN (1) | CN103038250A (en) |
| AP (1) | AP3286A (en) |
| AR (1) | AR081975A1 (en) |
| AU (1) | AU2011269427A1 (en) |
| BR (1) | BR112012033227A2 (en) |
| CA (1) | CA2802889A1 (en) |
| CL (1) | CL2012003643A1 (en) |
| CO (1) | CO6660484A2 (en) |
| EA (1) | EA201291233A1 (en) |
| EC (1) | ECSP12012351A (en) |
| MX (1) | MX2012014774A (en) |
| NZ (1) | NZ604033A (en) |
| PE (1) | PE20130326A1 (en) |
| PH (1) | PH12012502461A1 (en) |
| SG (1) | SG186276A1 (en) |
| TN (1) | TN2012000567A1 (en) |
| TW (1) | TW201202265A (en) |
| UY (1) | UY33462A (en) |
| WO (1) | WO2011160630A2 (en) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607150C (en) | 2005-05-04 | 2014-08-05 | Bjarne Due Larsen | Glucagon-like-peptide-2 (glp-2) analogues |
| WO2008056155A1 (en) | 2006-11-08 | 2008-05-15 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| MX2011006314A (en) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Glucagon analogues. |
| CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| EA020596B1 (en) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Glucagon analogues |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AR081975A1 (en) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | GLUCAGON ANALOGS |
| MA34383B1 (en) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | GLUCAGON ANALOGUES |
| SG192038A1 (en) * | 2011-01-20 | 2013-08-30 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| EP2758426B1 (en) | 2011-09-23 | 2019-08-07 | Novo Nordisk A/S | Novel glucagon analogues |
| SG11201403377QA (en) * | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| AR090937A1 (en) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS FOR USE |
| CN104540850B (en) * | 2012-05-03 | 2018-05-18 | 西兰制药公司 | Glucagon-like peptide 2 (GLP-2) analogs |
| EA201590011A1 (en) | 2012-06-14 | 2015-05-29 | Санофи | PEPTIDE ANALOGUES EXENDIN-4 |
| TWI642682B (en) | 2012-07-23 | 2018-12-01 | 丹麥商西蘭製藥公司 | Glucagon analog |
| TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analog |
| US9546205B2 (en) | 2012-09-17 | 2017-01-17 | Imperial Innovations Limited | Peptide analogues of glucagon and GLP1 |
| GB2505941A (en) * | 2012-09-17 | 2014-03-19 | Imp Innovations Ltd | Peptide analogues of glucagon for the treatment of obesity and diabetes |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| MA38276B1 (en) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Derivatives of exendin 4 for use in the treatment of metabolic syndrome disorders, including diabetes and obesity, as well as the reduction of excessive dietary intake. |
| SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
| MX362275B (en) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use. |
| DK3057984T3 (en) | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| TWI670281B (en) | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Gip-glp-1 dual agonist compounds and methods |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6898231B6 (en) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | GIP agonist compounds and methods |
| EP3673900B1 (en) | 2015-02-17 | 2025-06-25 | Amphastar Pharmaceuticals, Inc. | Nasal powder formulation for treatment of hypoglycemia |
| CA2979950A1 (en) | 2015-03-18 | 2016-09-22 | Zealand Pharma A/S | Amylin analogues |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| RU2735762C2 (en) | 2015-04-16 | 2020-11-06 | Зилэнд Фарма А/С | Acylated glucagon analogue, use thereof and methods of producing |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
| EP3468569A4 (en) | 2016-06-09 | 2020-05-27 | AmideBio LLC | GLUCAGON ANALOG AND METHOD FOR USE THEREOF |
| WO2018024653A1 (en) | 2016-08-05 | 2018-02-08 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| KR101887577B1 (en) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof |
| AR110299A1 (en) | 2016-12-02 | 2019-03-13 | Sanofi Sa | CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid |
| JP6563614B1 (en) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア／エス | Acylated GLP-1 / GLP-2 dual agonist |
| CN118526577A (en) | 2017-06-16 | 2024-08-23 | 西兰制药公司 | Dosage regimen for administration of glucagon-like peptide 2 (GLP-2) analogs |
| ES2973986T3 (en) * | 2017-08-16 | 2024-06-25 | Dong A St Co Ltd | Acylated peptide analogue of oxyntomodulin |
| BR112020014436A2 (en) | 2018-02-02 | 2020-12-01 | Boehringer Ingelheim International Gmbh | triazolopyrimidine derivatives, pharmaceutical composition and their uses as ghrelin o-acyl transferase (goat) inhibitors |
| CA3087827A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| KR20200116978A (en) | 2018-02-02 | 2020-10-13 | 베링거 인겔하임 인터내셔날 게엠베하 | Benzyl-substituted, (pyridin-3-yl)methyl-substituted or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CA3096493A1 (en) * | 2018-04-10 | 2019-10-17 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
| BR112020020647A2 (en) | 2018-04-10 | 2021-02-23 | Sanofi-Aventis Deutschland Gmbh | synthesis of lixisenatide with capping |
| US20220153853A1 (en) | 2018-12-21 | 2022-05-19 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific protein |
| TWI771669B (en) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | Method for preparing stable peptide formulations |
| CA3147770A1 (en) * | 2019-08-13 | 2021-02-18 | Jae Ha Ryu | Exenatide analog and use thereof |
| WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
| ES2984466T3 (en) | 2020-05-22 | 2024-10-29 | Boehringer Ingelheim Int | Manufacturing process for alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridinecarboxylate |
| CN115916789B (en) | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | Continuous process for preparing alkyl 7-amino-5-methyl- [1,2,5] oxadiazolo [3,4-b ] pyridine carboxylic acid esters |
| CN113292646B (en) * | 2020-05-29 | 2022-05-13 | 东莞云璟生物技术有限公司 | GLP-1/glucagon dual agonist fusion proteins |
| KR20230045088A (en) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Soluble NPY2 receptor agonists |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| WO1998011126A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| ES2294822T3 (en) | 1997-11-14 | 2008-04-01 | Amylin Pharmaceuticals, Inc. | NEW COMPOUNDS OF EXENDINE AGONISTS. |
| JP4394279B2 (en) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | Pharmacologically active peptide conjugates with reduced propensity to enzymatic hydrolysis |
| JP3702181B2 (en) | 1998-12-07 | 2005-10-05 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Analogs of GLP-1 |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| SK2432004A3 (en) | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Insulin compound having protracted activity |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| AU2004234345A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| JP2008543816A (en) | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | Novel compounds and their effects on eating behavior |
| WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| CN101534846B (en) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | Glucagon analogs exhibiting physiological solubility and stability |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| CN101389648B (en) | 2006-02-22 | 2013-07-17 | 默沙东公司 | Peptide oxyntomodulin derivative |
| CN101622276B (en) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | Antagonistic antibodies against EPHA2 for the treatment of cancer |
| ES2554773T3 (en) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulin and fibrillation resistant insulin analogues |
| TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| JP5385266B2 (en) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | Glucagon analog |
| MX338336B (en) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Modified insulin polypeptides and their uses. |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| DE102008003568A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | New insulin analogs useful for treating diabetes |
| KR20100111683A (en) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008003566A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | New insulin analogs useful for treating diabetes |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| KR20110021758A (en) | 2008-04-22 | 2011-03-04 | 케이스 웨스턴 리저브 유니버시티 | Exotype-Specific Insulin Analogs |
| TWI451876B (en) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | Pegylated insulin lispro compounds |
| CL2009001424A1 (en) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Glucagon-like peptide; dimer comprising two of said peptides; pharmaceutical composition comprising it; and its use to treat diabetes or induce weight loss. |
| AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| PL219335B1 (en) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | New slow-release insulin analogues |
| KR20110061552A (en) | 2008-07-31 | 2011-06-09 | 케이스 웨스턴 리저브 유니버시티 | Halogen stabilized insulin |
| MX2011006314A (en) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Glucagon analogues. |
| CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070251A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| EA020596B1 (en) * | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Glucagon analogues |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010080606A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Insulin analogs |
| CN101519446A (en) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | Method for preparing recombinant human insulin and analogs of recombinant human insulin |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AU2011206979B2 (en) | 2010-01-20 | 2015-09-10 | Zealand Pharma A/S | Treatment of cardiac conditions |
| AR081975A1 (en) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | GLUCAGON ANALOGS |
| MA34383B1 (en) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | GLUCAGON ANALOGUES |
| SG192038A1 (en) | 2011-01-20 | 2013-08-30 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| SG11201403377QA (en) | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analog |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| DK3057984T3 (en) | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
-
2011
- 2011-06-22 AR ARP110102166A patent/AR081975A1/en unknown
- 2011-06-22 UY UY0001033462A patent/UY33462A/en not_active Application Discontinuation
- 2011-06-23 EA EA201291233A patent/EA201291233A1/en unknown
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/en active Pending
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/en not_active Expired - Fee Related
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/en not_active IP Right Cessation
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/en not_active Withdrawn
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/en not_active Application Discontinuation
- 2011-06-23 TW TW100122081A patent/TW201202265A/en unknown
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 AP AP2013006669A patent/AP3286A/en active
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/en not_active Application Discontinuation
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
-
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/en unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/en unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/en unknown
-
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2585481B1 (en) | 2015-08-19 |
| WO2011160630A2 (en) | 2011-12-29 |
| UY33462A (en) | 2012-01-31 |
| NZ604033A (en) | 2014-12-24 |
| US9403894B2 (en) | 2016-08-02 |
| PH12012502461A1 (en) | 2013-02-18 |
| JP5937582B2 (en) | 2016-06-22 |
| EA201291233A1 (en) | 2013-07-30 |
| AP2013006669A0 (en) | 2013-01-31 |
| EP2585481A2 (en) | 2013-05-01 |
| TW201202265A (en) | 2012-01-16 |
| TN2012000567A1 (en) | 2014-04-01 |
| MX2012014774A (en) | 2013-01-29 |
| US20160304576A1 (en) | 2016-10-20 |
| WO2011160630A3 (en) | 2012-02-16 |
| KR20130086339A (en) | 2013-08-01 |
| JP2013534919A (en) | 2013-09-09 |
| AR081975A1 (en) | 2012-10-31 |
| CN103038250A (en) | 2013-04-10 |
| AP3286A (en) | 2015-05-31 |
| US20130157935A1 (en) | 2013-06-20 |
| CL2012003643A1 (en) | 2013-08-02 |
| BR112012033227A2 (en) | 2017-06-20 |
| CO6660484A2 (en) | 2013-04-30 |
| SG186276A1 (en) | 2013-01-30 |
| AU2011269427A1 (en) | 2012-12-20 |
| ECSP12012351A (en) | 2013-01-31 |
| CA2802889A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130326A1 (en) | GLUCAGON ANALOGS | |
| PE20130338A1 (en) | GLUCAGON ANALOGS | |
| PE20142113A1 (en) | GLUCAGON ANALOGS | |
| NZ597554A (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
| PE20160683A1 (en) | ACCURATE GLUCAGON ANALOGS | |
| NZ597981A (en) | Acylated glucagon analogues | |
| MX2010004297A (en) | Glucagon antagonists. | |
| NZ589847A (en) | Glucagon/glp-1 receptor co-agonists | |
| PE20121393A1 (en) | PEPTIDE ANALOGUE OF OXYNTHOMODULIN | |
| MX2010004298A (en) | Compounds exhibiting glucagon antagonist and glp-1 agonist activity. | |
| PE20140186A1 (en) | GLUCAGON ANALOGS PRESENTING GIP RECEPTOR ACTIVITY | |
| PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| PE20231639A1 (en) | CO-AGONIST COMPOUNDS OF GLUCAGON AND GLUGACON-LIKE PEPTIDE-1 (GLP-1) | |
| AR091866A1 (en) | GLUCAGON ANALOGS | |
| WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
| AR081339A1 (en) | PEPTIDIC CONJUGATES | |
| AR070119A1 (en) | INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / ACTION PROFILE | |
| AR088161A1 (en) | GLUCAGON ANALOGS | |
| PE20191083A1 (en) | DUAL ACCYLATED GLP-1 / GLP-2 AGONISTS | |
| PE20200678A1 (en) | DOSAGE FOR THE ADMINISTRATION OF GLUCAGON-2 TYPE PEPTIDE ANALOGS (GLP-2) | |
| CL2012002031A1 (en) | Pharmaceutical composition containing at least one fgf-21 compound (fibroblast growth factor 21) and at least one glp-1r agonist (glucagon-like peptide 1 receptor); and its use to prepare a medicament for the treatment of at least one metabolic syndrome and / or atherosclerosis in a patient. | |
| TN2009000313A1 (en) | Glucagon/glp - 1 receptor co-agonists | |
| AR067972A1 (en) | COMPOSITIONS OF PHENYLALANINAMONIACOLIASA PROCARIONTES AND USE OF ITS COMPOSITIONS IN METHODS TO TREAT CANCER | |
| MY152979A (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| PE20140160A1 (en) | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |